REFERENCES:

1. Bradley A. J., Breen J. E., White V., & Green M. J. (2015) An investigation of the efficacy of a polyvalent mastitis vaccine using different vaccination regimens under field conditions in the United Kingdom. Journal of Dairy Science, 98(3), 1706-1720.

2. Collado R., Montbrau C., Sitjà M., & Prenefeta A. (2018) Study of the efficacy of a Streptococcus uberis mastitis vaccine against an experimental intramammary infection with a heterologous strain in dairy cows. Journal of Dairy Science, 101(11), 10290-10302.

3. Nodar L., Angelats D., Hartjes J., Pochodyla M., Cepeda R., Villoria P. (2022) Statistical analysis of 33 Dutch farms of several udder health KPIs and antibiotic usage before and after using a polyvalent mastitis vaccine (against Staphylococcus aureus, Non-S. aureus staphylococci, Escherichia coli and coliforms). World Buiatrics Congress, Madrid, 2022.

4. Olde Riekerink R. G. M., Barkema H. W., Kelton D. F., Scholl D. T. (2008) Incidence rate of clinical mastitis on Canadian Dairy Farms. Journal of Dairy Science, 91(4), 1366-1377.

5. Puig A., Perozo E., Roura F., Armengol R., Mallo J., Echevarria J. M., Arrieta C., Herrera D., Fraquesa O., Hurtado L., Calm I., Collado R., Prenefeta T. & March R. (2018) Efficacy under field conditions of the new vaccine UBAC® in the reduction of Streptococcus uberis clinical mastitis in dairy cows during a whole lactation period. National Mastitis Council Regional Meeting, Milan, 318-319.

6. Schukken Y. H., Bronzo, V., Locatelli C., Pollera C., Rota N., Casula, A., Testa F., Scaccaborozzi L., March R., Zalduendo D., Guix R. & Moroni P. (2014) Efficacy of vaccination on Staphylococcus aureus and coagulase-negative Staphylococci intramammary infection dynamics in two dairy herds. Journal of Dairy Science, 97(8), 5250-5264.

PRODUCT INFORMATION:

STARTVAC® Polyvalent inactivated vaccine, bovine mastitis, in injectable emulsion for use in healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence and the severity of the signs of clinical or sub-clinical mastitis caused by Staphylococcus aureus, coliforms or coagulase-negative staphylococci. Contains Escherichia coli (J5) inactivated > 50 RED60* Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing Slime Associated Antigenic Complex (SAAC) > 50 RED80** *RED60: Rabbit effective dose in 60 % of the animals (serology). **RED80: Rabbit effective dose in 80 % of the animals (serology). UK: POM-V. ROI: POM.

UBAC® For active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by Streptococcus uberis, to reduce the somatic cell count in Streptococcus uberis positive quarter milk samples and to reduce milk production losses caused by Streptococcus uberis intramammary infections. Contains: Lipoteichoic acid (LTA) from Biofilm Adhesion Component (BAC) of Streptococcus uberis, strain 5616 ≥ 1 RPU. Montanide ISA 907.1 mg. Monophosphoryl Lipid A (MPLA). UK: POM-V. ROI: POM.

For more information about side-effects, precautions, warnings and contra-indications please refer to the packaging or product leaflet. Further information available from SPC or on www.hipra.com. Under veterinary prescription, consult your veterinary prescriber for further advice. Use medicines responsibly.

Safety and efficacy of these products together have not been evaluated. A decision to use either of these vaccines before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.